Dr. Marino is a Professor in the Department of Pathology at the University of Chicago, Biological Sciences Division. She is the founding Director of the Transplant Immunology and Immunogenetics Laboratory Section, and the Program Director of the American Society for Histocompatibility and Immunogenetics approved Histocompatibility and Immunogenetics Fellowship. Dr. Marino is board certified by The American College of Histocompatibility & Immunogenetics (ACHI).
Dr. Marino has identified, characterized, and published several new HLA alleles, co-authored book chapters, and published manuscripts in peer-reviewed scientific journals. In addition, she has been an invited speaker at local, national, and international meetings. Her primary clinical research interests are identifying pre-and post-transplant biomarkers of immunological risk to increase access and survival to solid organ transplant patients and to use genomic markers for hematopoietic cell transplant donor selection to reduce incidence and severity of graft-versus-host disease and to increase patient survival. In collaboration with the National Marrow Donor Program and the Center for International Blood and Marrow Transplant Research, Dr. Marino has identified permissive mismatches in hematopoietic cell transplantation and recently published the guidelines for the selection of Unrelated Donors and Cord Blood Units for Hematopoietic Cell Transplantation.
High-resolution HLA allele and haplotype frequencies in several unrelated populations determined by next generation sequencing: 17th International HLA and Immunogenetics Workshop joint report.
High-resolution HLA allele and haplotype frequencies in several unrelated populations determined by next generation sequencing: 17th International HLA and Immunogenetics Workshop joint report. Hum Immunol. 2021 Jul; 82(7):505-522.
PMID: 34030896
An association between resting state EEG parameters and the severity of topiramate-related cognitive impairment.
An association between resting state EEG parameters and the severity of topiramate-related cognitive impairment. Epilepsy Behav. 2021 01; 114(Pt A):107598.
PMID: 33268020
Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research.
Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2020 03; 26(3):553-561.
PMID: 31726205
Effective desensitization for a strong donor-specific HLA antibody in a case of HLA-mismatched allogeneic hematopoietic cell transplantation.
Effective desensitization for a strong donor-specific HLA antibody in a case of HLA-mismatched allogeneic hematopoietic cell transplantation. HLA. 2019 09; 94(3):307-311.
PMID: 31314169
Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR.
Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. Blood. 2019 09 19; 134(12):924-934.
PMID: 31292117
HLA alleles and haplotypes observed in 263 US families.
HLA alleles and haplotypes observed in 263 US families. Hum Immunol. 2019 Sep; 80(9):644-660.
PMID: 31256909
Quality control project of NGS HLA genotyping for the 17th International HLA and Immunogenetics Workshop.
Quality control project of NGS HLA genotyping for the 17th International HLA and Immunogenetics Workshop. Hum Immunol. 2019 Apr; 80(4):228-236.
PMID: 30738112
Reanalysis of the role of pronase treatment of B cells in the flow cytometric crossmatch assay: Fc receptor is not the primary target.
Reanalysis of the role of pronase treatment of B cells in the flow cytometric crossmatch assay: Fc receptor is not the primary target. Hum Immunol. 2017 Nov; 78(11-12):704-709.
PMID: 28987959
Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases.
Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. Haematologica. 2017 11; 102(11):1823-1832.
PMID: 28818869
EDTA is superior to DTT treatment for overcoming the prozone effect in HLA antibody testing.
EDTA is superior to DTT treatment for overcoming the prozone effect in HLA antibody testing. HLA. 2017 02; 89(2):82-89.
PMID: 28102038
PI: Computational simulation tools to predict donor compatibility in HCT
Center for International Blood and Marrow Transplant Research (CIBMTR)
2015 - 2017
PI: Effects of HLA class I amino acid mismatches on stem cell transplant outcomes
Center for International Blood and Marrow Transplant Research (CIBMTR)
2013 - 2017
PI: HLA mismatches at the amino acid level on hematopoietic stem cell transplant
Center for International Blood and Marrow Transplant Research (CIBMTR)
2007 - 2017
PI: HLA matching in pediatric unrelated umbilical cord blood transplantation
Center for International Blood and Marrow Transplant Research (CIBMTR)
2004
PI: DNA-based HLA class I typing contract
National Marrow Donor Program (NMDP)
1997 - 1998
PI: DNA-based HLA class II typing contract
National Marrow Donor Program (NMDP)
1995 - 1998
Qualitas Award, Dr. Alfredo Lanari
Academy Nacional of Sciences. Argentina
1990
1st Place, Best Thesis Annual School of Medicine
University of Buenos Aires
1989
Scholarship Recipient
Canadian Heart Foundation
1987
Scholar Recipient (not accepted)
The Kidney Foundation of Canada
1987